Use of dabigatran with antiretrovirals

Objectives Theoretical and untested interactions between antiretrovirals and direct‐acting oral anticoagulants have limited the use of this new class of anticoagulant in people with HIV infection. This case series, the first of its kind, reports on the successful concurrent use of the direct‐acting oral anticoagulant dabigatran and antiretroviral therapy. Methods This series involved 14 patients requiring anticoagulation for management of atrial fibrillation, who were either unable or unwilling to take warfarin, and who were receiving concurrent treatment for HIV infection. Participants were treated with dabigatran with dose monitoring to establish the safety and efficacy of concurrent use with antiretrovirals. All were commenced on 110 mg twice daily, increased to 150 mg twice daily if the trough level was < 69.3 ng/mL. Results In the 14 patients treated with dabigatran and antiretrovirals, there were no thromboembolic or bleeding complications. Dabigatran treatment was discontinued in one patient because of undetectable dabigatran levels despite dose escalation. Dabigatran levels fell within the fivefold variance seen in the Randomized Evaluation of Long‐Term Anticoagulation Therapy ( RE ‐ LY ) study at a dose of either 110 or 150 mg twice daily. Conclusions This case series represents the largest published population to date successfully receiving antiretroviral and direct‐acting oral anticoagulant therapy. Given the significant health care burden faced by people living with HIV , the availability of safe anticoagulant therapy without the requirement for monitoring is an important option in this patient population.